← Leaderboards
John Levine
University Of Michigan At Ann Arbor
$11,621,840
Attributed
$11,621,840
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,621,840 · 9
FDA$0 · 1
By mechanism
P01$8,264,052 · 4
UG1$1,701,765 · 1
R34$687,930 · 1
K23$680,400 · 1
U10$160,943 · 1
R21$126,750 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Jason Spence$16,355,373
- Linda C Samuelson$12,939,157
- Pavan Reddy$35,237,005
- Deborah L. Gumucio$17,750,962
- Paul B Watkins$20,798,906
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsAllogenicComplicationBone Marrow TransplantationSteroidsBiological MarkersTransplantationHematopoietic Stem Cell TransplantationHigh RiskSymptomsModalityMalignant - DescriptorBaseDoseAcute Graft Versus Host DiseaseMolecularT-LymphocyteAllogeneic Bone Marrow TransplantationGastrointestinal Tract StructureMortalityClinical ResearchGraft-Vs-Host DiseaseBloodRegimen
Grant awards (40)
Project 3: Risk Adapted Clinical Trials of GVHD Treatment$677,070
P01 · FY2025 · CA · contact PI
BMT CTN Core - Mount Sinai Consortium$219,211
UG1 · FY2025 · HL · contact PI
Validation of a novel and more accurate endpoint for GVHD clinical trials$126,750
R21 · FY2025 · HL · contact PI
Project 3: Risk Adapted Clinical Trials of GVHD Treatment$643,217
P01 · FY2024 · CA · contact PI
BMT CTN Core - Mount Sinai Consortium$251,775
UG1 · FY2024 · HL · contact PI
Project 3: Risk Adapted Clinical Trials of GVHD Treatment$677,070
P01 · FY2023 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$173,337
UG1 · FY2023 · HL · contact PI
Project 3: Risk Adapted Clinical Trials of GVHD Treatment$647,867
P01 · FY2022 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$173,337
UG1 · FY2022 · HL · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$173,337
UG1 · FY2021 · HL · contact PI
Project 3: Clinical Trials of High Risk GVHD$591,471
P01 · FY2020 · CA · contact PI
Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers$402,888
P01 · FY2020 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$173,337
UG1 · FY2020 · HL · contact PI
Project 3: Clinical Trials of High Risk GVHD$573,726
P01 · FY2019 · CA · contact PI
Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers$390,802
P01 · FY2019 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$173,337
UG1 · FY2019 · HL · contact PI
Project 3: Clinical Trials of High Risk GVHD$569,191
P01 · FY2018 · CA · contact PI
Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers$399,404
P01 · FY2018 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$170,861
UG1 · FY2018 · HL · contact PI
Project 3: Clinical Trials of High Risk GVHD$532,520
P01 · FY2017 · CA · contact PI
Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers$362,733
P01 · FY2017 · CA · contact PI
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network$193,233
UG1 · FY2017 · HL · contact PI
Project 3: Clinical Trials of High Risk GVHD$420,650
P01 · FY2016 · CA · contact PI
Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers$362,733
P01 · FY2016 · CA · contact PI
GVHD Clinical Trials and Biomarkers$195,902
P01 · FY2014 · CA · contact PI
University of Michigan Core Clinical Center for BMT Research Network$160,943
U10 · FY2014 · HL · contact PI
GVHD Clinical Trials and Biomarkers$259,935
P01 · FY2013 · CA · contact PI
Phase II Study of a Novel GVHD Prevention Strategy: Etanercept and Photopheresis$222,054
R34 · FY2013 · HL · contact PI
Phase II Study of a Novel GVHD Prevention Strategy: Etanercept and Photopheresis$233,250
R34 · FY2012 · HL · contact PI
GVHD Clinical Trials and Biomarkers$183,624
P01 · FY2012 · CA · contact PI
Phase II Study of a Novel GVHD Prevention Strategy: Etanercept and Photopheresis$232,626
R34 · FY2011 · HL · contact PI
GVHD Clinical Trials and Biomarkers$183,750
P01 · FY2011 · CA · contact PI
GVHD Clinical Trials and Biomarkers$189,499
P01 · FY2010 · CA · contact PI
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$68,040
K23 · FY2006 · CA · contact PI
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$136,080
K23 · FY2005 · CA
Treatment of Graft-versus-Host Disease Using Enbrel$0
R01 · FY2005 · FD
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$136,080
K23 · FY2004 · CA
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$136,080
K23 · FY2003 · CA
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$68,040
K23 · FY2002 · CA
CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY$136,080
K23 · FY2001 · CA